Tom Reichert received his PhD in Physical Chemistry from UC Berkeley in 1969.  After post-doctoral stints in Physics and Biomedical Engineering, Tom joined the faculty at Carnegie-Mellon University in Electrical and Biomedical Engineering, and went on to head the Biotechnology Program at that University.  In 1973, he formed a partnership, Entropy Limited, to study and propagate the use of entropy extrema in solution of problems of societal interest.  In 1976, he decided that as a bioengineer, he lacked sufficient clinical perspective, so he left C-MU for medical school at the University of Miami, and residency (Internal Medicine), fellowship (Medical Oncology) and a faculty position at Duke University.  In 1984, the opportunity arose to be the first medical director for a company (Becton Dickinson) that was developing two technologies, the diagnostic tool, flow cytometry, and the pharmaceutical entity, monoclonal antibodies.  Tom co-holds a patent in machine vision that transformed the way the humans interact with the multi-dimensional data produced by flow cytometers; and this technology has become the standard by which progression of HIV disease is measured, and by which cellular phenomena are studied in research.  In 1990, Tom became Corporate Vice President for Medical Affairs for B-D, a position he held for a decade.  In this position, he worked to transform product development moving tools such as fractional factorial design into the clinical trials mainstream; and used predictive tools to analyze both product pipelines and corporate financial performance.  He “retired” on the last day of the last century to follow the question, “Why do more people die in the winter?”.  This research has been advanced in collaboration with the US NIH under a protocol entitled Multinational Influenza Seasonal Mortality Study (MISMS) that has attracted collaborators from 12 countries.  He currently has about 50 publications with several in the works.  Tom also consults for a variety of companies on clinical trial design and strategy.